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The presence of lipids and lipoproteins in syn-
thetic vascular grafts that are implanted in animals
and in humans is well documented.1-4 In fact, graft
implants in animals and failed grafts removed from
humans show elevated amounts of lipid compared
with native aorta.5 The morphologic condition of
the accumulated lipids in grafts resembles human
atherosclerotic lesions, with cholesterol clefts, lipid
bodies in the extracellular matrix, and foamy lipid
deposits in macrophages.6 Interestingly, the deposi-
tion of lipoproteins in vascular grafts is not uniform.
Low density lipoprotein (LDL) labeled with iodine
125 preferentially accumulated at graft anastomoses,
the very regions where anastomotic intimal hyper-
plasia develops, in two separate studies that used a
rabbit model.5,7 The relationship between LDL
accumulation and intimal hyperplasia is not known,
but the parallels with atherosclerosis suggest a
causative relationship.
An important role for oxidized LDL in the devel-
opment of atherosclerosis is suggested by the multi-
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ple lines of evidence both in vivo and in vitro.
Oxidized LDL has been found in human atheroscle-
rotic lesions, and antibodies raised against oxidized
LDL recognize epitopes that are present in athero-
sclerotic lesions.8 Antibodies to oxidized LDL have
been found in the plasma of patients with cardiovas-
cular disease,9 and the level of these antibodies cor-
relates with the degree of disease. In vitro studies
show that oxidized LDL is chemotactic for mono-
cytes, induces foam cell formation, inhibits endothe-
lial cell (EC) migration, and increases smooth muscle
cell (SMC) proliferation and matrix deposition.10-16
Despite the considerable attention given to the
role of oxidized LDL in the development of athero-
sclerosis, the role of oxidized LDL in graft failure
has not been studied extensively. After graft implan-
tation, an inflammatory response occurs, with many
of the same dysfunctional cellular responses found in
atherosclerosis (namely, monocyte chemotaxis, lim-
ited EC migration, and SMC proliferation).6 The
similarity of cellular dysfunction in vascular graft
healing and atherosclerosis suggests that oxidized
lipids may also play a role in vascular graft failure.
Our work suggests that lipid oxidation products are
present in both Dacron and expanded polytetrafluo-
roethylene (ePTFE) grafts explanted from rabbit
and canine models.17 A single study suggests that
failed human vein grafts have elevated levels of lipid
peroxides.18 Because LDL is preferentially deposited
at graft anastomoses,5,7 anastomotic sites may be
particularly prone to the accumulation of oxidized
lipids and lipoproteins, but the role of oxidized
lipids in graft failure has not been investigated.
Oxidized LDL is present in atherosclerotic
lesions, but the mechanism of oxidation in vivo is
not known. EC and SMC oxidize LDL in vitro but
require the presence of exogenous transition metal
ions.19,20 Thus both of these cell types could partic-
ipate in LDL oxidation within the atherosclerotic
lesion or graft environment if unbound copper or
iron is available.21,22 In contrast to EC and SMC,
monocytes/macrophages can oxidize LDL by a
mechanism that may not require exogenous metal
ions.23,24 The only agent known to induce mono-
cytes to oxidize LDL in the absence of exogenous
metal ions is zymosan, a mixture of yeast cell wall
fragments,24,25 although more recent data suggest
that it may be metal ions within the zymosan prepa-
ration that induce monocytes to oxidize LDL.26
Monocytes are available to participate in LDL oxi-
dation in grafts because they invade the graft mater-
ial early after implantation, become resident in graft
interstices, and take up lipids.2,27 Monocytes and
macrophages are known to participate in a foreign-
body response to an implanted graft, and in vitro
studies suggest that graft materials stimulate mono-
cyte/macrophage production of cytokines,28,29
which may contribute to LDL modification. In the
present study, we tested the hypothesis that graft
materials may activate EC, SMC, and monocytic
cells to oxidize LDL and address the potential mech-
anisms of this oxidation.
METHODS
Reagents. Zymosan (from Saccharomyces cere-
visiae), cytochrome c (from horse heart), Cu/Zn-
superoxide dismutase (Cu/Zn-SOD; 3000 units/mg
protein from bovine erythrocytes), catalase (10,000-
30,000 units/mg protein, from bovine liver), cumene
hydroperoxide, deferoxamine, bathocuproinedisul-
fonic acid, cholesterol calibrators, glutaraldehyde,
M199, and other assay materials were purchased from
Sigma Chemical Company (St Louis, Mo). Malon-
dialdehyde bis (dimethyl acetal; MDA) was purchased
from Aldrich Chemicals (Milwaukee, Wis). Dialysis
membranes (12,000-14,000 molecular weight pores)
were obtained from Baxter Healthcare Corporation
(McGaw Park, Ill). L-glutamine and penicillin-strep-
tomycin, ethylenediaminetetra-acetic acid (EDTA),
and fetal bovine serum (FBS) were purchased from
Gibco BRL Life Technologies (Gaithersburg, Md).
Ammonium molybdate was purchased from Mallin-
ckrodt Chemical Works (Paris, Ky). Rosewell Park
Memorial Institute (RPMI) 1640 colorless media
(without L-glutamine) was purchased from Bio-
Whittaker, Inc (Walkersville, Md). Collagenase A,
elastase type II, soybean trypsin inhibitor, and bovine
serum albumin were obtained from Boehringer
Mannheim (Indianapolis, Ind). Triton-X 100 was
purchased from Fisher Scientific (Fairlawn, NJ).
Agarose gels (1%) were obtained from Ciba Corning
Diagnostics (Alameda, Calif). Dacron Cooley double
velour–knitted graft material was obtained from
Meadox Medicals, Inc (Oakland, NJ), and ePTFE
graft material was obtained from W.L. Gore and
Associates (Flagstaff, Ariz). Monoclonal antibodies
against factor VIII-related antigen were obtained
from Chemicon International (Temecula, Calif).
Antibody to smooth muscle–specific α-actin was
obtained from Sigma Chemical Company.
Lipoprotein preparation. Human LDL (densi-
ty, 1.019-1.063 g/mL) was prepared by sequential
ultracentrifugation of freshly drawn, citrated plasma
to which EDTA was added before centrifugation.30
Before use, LDL was dialyzed at 4°C for 48 hours
against 0.9% saline solution to remove the EDTA.
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Graft preparation. Graft material sections (80
± 5 mg/cm2/well, cut in squares approximately
1.25 × 1.25 cm) were washed in 10 mmol/L EDTA
to remove any contaminating divalent metal ions,
then washed three times with phosphate-buffered
saline solution at pH 8.0 to remove the EDTA, five
times with ethanol (100%), and five times with
deionized (Milli-Q Plus; Millipore Corp, Bedford,
Mass) water. The graft material was air dried
overnight and plasma sterilized. Before use, ePTFE
was briefly placed again in ethanol 100%, followed
immediately by RPMI to avoid air bubbles within
the graft material. Graft material was then placed
into 48-well plates. Cells in RPMI medium were
added on top of the graft material and incubated
with LDL for 24 hours.
Cell culture. U937 cells, a monocytic cell line,
were obtained from American Type Culture
Collection (Rockville, Md). Cells were maintained
in RPMI 1640 medium (which contains no added
transition metal ions) with 5% FBS, 2% L-glutamine,
and 1% penicillin-streptomycin. All experiments
were performed with colorless RPMI 1640 medium
in 48-well plates.
Human peripheral monocytes were isolated from
30 mL of freshly drawn human blood mixed with
3.8% sodium citrate. Ficoll was added, and the blood
was centrifuged at 440g. The intermediate ficoll layer
that contained white cells was collected and passed
through a magnetic column coated with antibodies to
all white cells except to monocytes.31 Monocytes were
collected from the column, placed in colorless RPMI
1640 medium, and immediately seeded into 48-well
plates at a density of 500,000/mL. Purity was deter-
mined to be 98% to 99% by CD14 staining.
ECs were harvested from canine aorta. Aortic
segments were incubated in collagenase A (630
U/mL) for 10 minutes at 37°C in a 5% carbon diox-
ide atmosphere. ECs were removed by gentle scrap-
ing, then cultured in 6-well plates coated with
fibronectin, and grown in M199 with 20% FBS. At
confluence, the medium was changed to RPMI
1640. EC purity was confirmed with monoclonal
antibodies against factor VIII–related antigen. All
experiments were performed with first-passage EC.
SMCs were harvested from canine aortas after a
second, more vigorous scraping to remove all ECs.
The medial layer was then stripped from the aorta
and incubated for 2 hours (while being shaken) with
5 mL of M199 containing 2 mg/mL bovine serum
albumin, 0.375 mg/mL soybean trypsin inhibitor,
15 U/mL elastase type II, and 170 U/mL collage-
nase A. The medium was centrifuged at 300g for 5
minutes, and the pellet was resuspended in M199
with 20% FBS. SMCs were cultured in 6-well culture
plates and grown to confluence. SMC purity was
confirmed with antibody to smooth muscle–specific
α-actin. The medium was then changed to RPMI
1640. All experiments were performed with first-
passage SMC.
Measurement of LDL oxidation and superox-
ide production. Cholesterol was measured with
cholesterol calibrators, and oxidation was measured
by four different assays: thiobarbituric acid–reacting
substances (TBARS), conjugated dienes, lipid per-
oxides, and electrophoretic mobility. TBARS were
measured by the method of Schuh et al.32 Samples
were analyzed by fluorimeter with excitation at 515
nm and emission at 553 nm. TBARS were expressed
as nanomole MDA per milligram of cholesterol.
Conjugated dienes were measured spectrophoto-
metrically by absorbance at 233 nm.33 Lipid perox-
ides were measured by the method of El-Saadani et
al.34 Electrophoretic mobility was determined with
the use of 1% agarose gel electrophoresis.
Superoxide production was measured spectropho-
tometrically as Cu/Zn-SOD–inhibited reduction of
ferricytochrome c.35,36 Cultured cells were incubated
for 2 hours at 37°C in colorless RPMI 1640 medium.
SOD-inhibitable superoxide was determined as the
difference in absorbance at 550 nm between cells
incubated with and without SOD (150 U/mL), and
amounts of superoxide were calculated with an extinc-
tion coefficient of 21.1/mmol/L. Cell-free wells
were used as controls.
Scanning electron microscopy. Graft sections
were fixed in 2.5% glutaraldehyde for 24 hours,
dehydrated in graded alcohols, dried in hexamethyl-
disilazine, sputter coated with gold, and analyzed by
scanning electron microscopy (SEM).
All experiments were done in triplicate, unless
otherwise stated and results are expressed as the
mean ± SE of the mean.
RESULTS
Effect of graft materials on oxidation by
U937 cells. The ability of Dacron and ePTFE graft
material to stimulate LDL oxidation was assessed by
incubation of U937 cells for 24 hours with LDL in
the presence or absence of graft material. U937 cells
incubated with Dacron graft material induced an 18-
fold increase in LDL oxidation compared with cells
alone, as measured by TBARS, although ePTFE
induced only a 3-fold increase (n = 20; Fig 1, A).
Zymosan, the only agent known to induce mono-
cytic cell oxidation in the absence of exogenous
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divalent metal ions, was used as a positive control
and induced a 24-fold increase in LDL oxidation.
When Dacron graft material was incubated with
LDL in the absence of U937 cells, no measurable
LDL oxidation occurred (results not shown), indi-
cating that Dacron graft did not directly cause LDL
oxidation but that the presence of both Dacron and
U937 cells was necessary for LDL oxidation. To ver-
ify that Dacron-activated U937 cells resulted in
LDL oxidation, the formation of conjugated dienes
and lipid peroxides and the changes in elec-
trophoretic mobility were assessed. Dacron-activat-
ed U937 cells resulted in a 5-fold increase in the for-
mation of conjugated dienes (Fig 1, B), a 3.5-fold
increase in lipid peroxide formation (Fig 1, C), and
an increase in electrophoretic mobility (results not
shown); ePTFE, on the other hand, caused minimal
LDL oxidation as determined by all of these assays.
Zymosan increased conjugated diene formation by
18-fold, and lipid peroxides increased it by 5-fold.
Because LDL oxidation is a dynamic process, a
time course for Dacron-activated U937 cell oxidation
of LDL was determined by TBAR assay (Fig 2).
Minimal oxidation occurred during the first 6 hours
of incubation. A rapid increase in oxidation was noted
between 6 and 12 hours. LDL oxidation then contin-
ued at a steady rate until 48 hours, after which time it
began to decline. Zymosan-activated U937 cell oxi-
dation of LDL followed a similar pattern. During the
96-hour time course, LDL in medium alone, LDL
with U397 cells alone, and LDL with Dacron graft
material alone were minimally oxidized.
Effect of graft materials on LDL oxidation by
canine EC and SMC. ECs and SMCs oxidize LDL
in vitro in a transition metal ion–dependent man-
ner.19,20 To determine whether graft material can
activate these vascular cells to oxidize LDL, canine
aortic ECs or SMCs were seeded onto ePTFE and
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Fig 1. LDL oxidation by graft-activated U937 cells.
Dacron and ePTFE graft material (80 ± 5 mg/mL) were
incubated for 24 hours with U937 cells (500,000/mL)
and LDL (500 µg cholesterol/mL.) The modified LDL
was then subjected to measurements of LDL oxidation,
including TBARS (A), conjugated dienes (B), and lipid
peroxides (C). The results shown are representative exper-
iments that were performed in triplicate.
Fig 2. Time course of LDL oxidation by Dacron-activat-
ed U937 cells. Dacron graft material was incubated with
U937 cells and LDL for times extending up to 96 hours.
LDL oxidation was measured by TBARS. Significant LDL
oxidation occurred after the first 6 hours of incubation of
U937 cells with Dacron graft material or zymosan.
A
B
C
Dacron graft material. ECs (Fig 3, A) or SMCs (Fig
3, B) on Dacron graft material did not augment LDL
oxidation. In a positive control experiment, CuSO4
stimulated LDL oxidation, both in the presence and
absence of cells. When both CuSO4 and Dacron graft
material were present, there was a decrease in LDL
oxidation; similarly, when CuSO4 and Dacron graft
material were coincubated with either EC or SMC, a
reduction, rather than an augmentation, in LDL oxi-
dation occurred. Similar results were obtained with
ePTFE graft material and are not shown.
The role of superoxide in Dacron-activated
U937 cell oxidation of LDL. The requirement
for superoxide production in zymosan-stimulated
monocyte oxidation of LDL has been shown by
some investigators24 but is questioned by others.37
We therefore studied the role of this reactive oxygen
species in LDL oxidation by Dacron-activated U937
cells. We first examined the ability of graft materials
to stimulate a respiratory burst in U937 cells.
Superoxide production was measured during a 2-
hour period after the addition of Dacron and ePTFE
graft materials. The short time period was chosen
because the monocyte/macrophage respiratory
burst occurs predominantly within the first 2 hours
after stimulation.38,39 Dacron induced at least a 4-
fold increase in superoxide production by U937 cells
(Fig 4), and in some experiments the measured
increase was greater than 10-fold (n = 5). ePTFE
graft material did not stimulate a measurable
increase in U937 cell production of superoxide.
Zymosan, the positive control, elicited at least a 2-
fold increase in superoxide production and as high as
a 5-fold increase. Thus the ability of Dacron and
ePTFE to stimulate U937 cell oxidation of LDL
correlated with their ability to induce a respiratory
burst in these cells.
The requirement of superoxide production in
Dacron-activated U937 cell oxidation of LDL was
determined by an assessment of the ability of
Cu/Zn-SOD to inhibit this oxidation. Cu/Zn-SOD
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Fig 3. The effect of Dacron graft material on LDL oxi-
dation by canine aortic EC and SMC. Canine aortic EC
and SMC were harvested from three animals and seeded at
a density of 200,000/cm2/well onto Dacron graft mater-
ial (80 mg/cm2/well). Cells were allowed to adhere to
the graft in RPMI with 20% FBS for 48 hours then were
washed. EC (A) and SMC (B) were then incubated in
serum-free RPMI, with LDL (500 µg/mL), in the pres-
ence or absence of CuSO4 (5 µmol/L). Neither EC nor
SMC were activated by Dacron graft material to oxidize
LDL. The results shown are representative experiments
that were performed in triplicate.
Fig 4. Superoxide production by graft-activated mono-
cytic cells. U937 cell production of superoxide in the pres-
ence of graft material was examined by ferricytochrome c
reduction over a 2-hour incubation period. Dacron graft
material, but not ePTFE, stimulated increased superoxide
production by U937 cells. Zymosan, the positive control,
also stimulated increased superoxide production by U937
cells. The results shown are representative experiments
that were performed in triplicate and are reported as
nanomoles of superoxide per milliter every 2 hours.
A
B
was added both before stimulation and 2 hours after
activation because the respiratory burst of mono-
cytes/macrophages is characterized by a production
of large quantities of proteases that may degrade
Cu/Zn-SOD.38 Cu/Zn-SOD reduced LDL oxida-
tion by 57%, 75%, and 82% as measured by TBARS,
conjugated dienes, and lipid peroxides, respectively
(Fig 5). In other experiments, catalase (1000
units/mL; an enzyme that degrades H202) and man-
nitol (a hydroxyl radical scavenger) did not inhibit
Dacron-activated U937 cell oxidation of LDL. These
results suggest that superoxide, but not H202 or
hydroxyl radical, is required for Dacron-activated
U937 cell oxidation of LDL.
Role of cell adherence in graft-activated
monocytic cell oxidation of LDL. To examine fur-
ther our findings that Dacron graft material activates
U937 to enter a respiratory burst and that ePTFE
does not, we postulated that there may be a variable
ability of monocytic cells to adhere to the two types
of graft material. As a result, U937 cells were incu-
bated with both graft materials in the presence and
absence of LDL. After 24 hours, the graft sections
were examined by SEM. ePTFE sections were cov-
ered with a relatively uniform layer of adherent
monocytes. Dacron material had clumps of adherent
cells, particularly in the crevices of the crimped mate-
rial. The number of monocytes did not differ signifi-
cantly when multiple sections of the two graft types
were averaged. No difference was seen between the
segments of the same material that were incubated
with cells alone (without LDL), or in the presence of
LDL (results not shown). Given this finding, mono-
cytic cell adherence did not appear to explain the dif-
ference in the ability of the two graft types to activate
monocytic cells to oxidize LDL.
Role of metal ions in Dacron activation of
U937 cells. Transition metal ions are capable of
propagating oxidative reactions. We therefore exam-
ined the role played by transition metal ions in
Dacron-activated U937 cell oxidation of LDL.
EDTA (a nonspecific divalent metal cation chelator),
deferoxamine (a specific Fe3+ chelator), and batho-
cuproinedisulfonic acid (a specific Cu1+ chelator)
were added to wells containing LDL, U937 cells,
and Dacron graft material. All three metal chelators
inhibited Dacron-activated U937 cell oxidation of
LDL (n = 3). EDTA and deferoxamine caused a
dose-dependent decrease in oxidation, with half-
maximal activity at approximately 1 µmol/L (Fig 6).
Bathocuproinedisulfonic acid, on the other hand,
did not cause inhibition until 100 µmol/L; lower
doses slightly augmented the oxidation seen with
Dacron-activated U937 cells. The slight increase in
LDL oxidation seen with bathocuproinedisulfonic
acid may be related to the presentation of metal ion
for oxidation reactions. Low levels of chelators, by
binding metal ions, can present the metal ions for
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Fig 5. Inhibition of LDL oxidation by superoxide dismu-
tase. The role of superoxide in Dacron-activated U937 cell
oxidation of LDL was examined by the addition of SOD
(150 units/mL) to Dacron graft material, U937 cells, and
LDL. LDL oxidation was measured at 24 hours by TBARS
(A), conjugated dienes (B), and lipid peroxides (C). By all
measurements of LDL oxidation, SOD resulted in the inhi-
bition of LDL oxidation. The results shown are represen-
tative experiments that were performed in triplicate.
A
B
C
redox reactions, thereby promoting oxidative reac-
tions.40 The EDTA and deferoxamine results indi-
cate that a divalent metal ion, possibly Fe2+, is
involved in Dacron-activated U937 cell oxidation of
LDL. The bathocuproinedisulfonic acid data indi-
cate the additional involvement of Cul+ in Dacron-
induced LDL oxidation.
Dacron graft material induces human mono-
cytes to oxidize LDL. To determine whether
Dacron graft material is capable of activating human
monocytes to oxidize LDL, human peripheral blood
monocytes were incubated with Dacron graft mate-
rial and LDL for a 48-hour time course (Fig 7).
Minimal oxidation occurred during the first 24
hours of incubation; however, significant oxidation
was noted during the second 24-hour period. SOD
inhibited LDL oxidation, indicating a potential role
for the superoxide in the Dacron-activated human
monocytic cell oxidation of LDL. The negative con-
trols (namely, medium with LDL, monocytes with
LDL alone, and Dacron graft material with LDL
alone) resulted in minimal LDL oxidation.
DISCUSSION
Previous work has demonstrated that zymosan, a
mixture of yeast cell wall fragments, activates U937
cells to oxidize LDL, an ability that was previously
considered unique to zymosan.24,25 Our work
demonstrates that Dacron graft material is also capa-
ble of activating U937 cells to oxidize LDL, begin-
ning approximately 6 hours after incubation and
reaching a plateau at 48 hours. The mechanism by
which zymosan exerts this effect is somewhat contro-
versial but is known to involve monocyte activation
and initiation of a respiratory burst.41 Cathcart et al24
have demonstrated that zymosan-induced U937 cell
production of superoxide is required for LDL oxida-
tion. Hiramatsu et al42 suggest that superoxide initi-
ates, but does not propagate, LDL oxidation. Jessup
et al37 and, more recently, Xing et al26 have argued
against any role for superoxide, maintaining instead
that transition metal ions in zymosan preparations
cause LDL oxidation. Based on this controversy, we
examined the role of both superoxide and transition
metal ions in Dacron-activated U937 cell oxidation
of LDL. Dacron was found to stimulate U937 cell
superoxide production to levels comparable to that
by zymosan. SOD significantly inhibited Dacron-
activated U937 cell oxidation of LDL, which indi-
cates an important role for superoxide production in
LDL oxidation. ePTFE did not stimulate measurable
levels of superoxide production by U937 cells, possi-
bly accounting for the minimal LDL oxidation by
U937 cells incubated with ePTFE.
Differences in the ability of Dacron and ePTFE
graft material to stimulate superoxide production by
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Fig 6. Inhibition of LDL oxidation by transition metal ion
chelators. Involvement of transition metal ions in Dacron-
activated U937 cell oxidation of LDL was tested with the
use of deferoxamine (a specific Fe3+ chelator), EDTA (a non-
specific divalent cation chelator), and bathocuproinedisul-
fonic acid (a specific Cu1+ chelator). These metal chelators
were coincubated for 24 hours with Dacron graft material,
U937 cells, and LDL. Each of these metal chelators resulted
in the inhibition of Dacron-activated U937 cell oxidation of
LDL. The results shown are representative experiments that
were performed in triplicate.
Fig 7. LDL oxidation by Dacron-activated human periph-
eral blood monocytes. Dacron graft material (80 ± 5
mg/mL) was incubated with human peripheral blood
monocytes (500,000/mL) and LDL (500 µg choles-
terol/mL) during a 48-hour time course. LDL oxidation
was measured by TBARS. The Dacron graft activated
human peripheral blood monocytes to oxidize LDL after 48
hours of incubation. A marked diminution in LDL oxidation
occurred when SOD was incubated with Dacron, human
monocytes, and LDL. The results shown are representative
experiments that were performed in triplicate.
U937 cells might be the result of differences in cell
adherence to the graft material. Examination of the
graft surfaces by SEM showed no dramatic differ-
ences in total cell number adherent to Dacron or
ePTFE. The Dacron graft material used was a dou-
ble velour–knitted material and thus has a larger sur-
face area than the ePTFE; cells located within the
graft interstices could not be quantitated. Within the
context of these limitations, it does not appear that
differences in cell adherence on Dacron and ePTFE
graft material account for the dramatic differences in
LDL oxidation.
Because transition metal ions may initiate
and/or propagate oxidative reactions,43 we explored
the importance of metal ions in LDL oxidation by
Dacron-activated U937 cells. Recent work by Xing
et al26 suggested that even monocytes and macro-
phages require transition metal ions to oxidize LDL,
which necessitates a careful search for possible
sources of metal ions in the incubation conditions.
The medium used for experiments contained no
added transition metal ions. Another possible source
of metal ions was the graft material. If the two graft
types contained variable amounts of transition metal
ions, this could account for the different ability to
activate cells to oxidize LDL. EDTA washes for
Dacron graft material, however, resulted in no
diminution in LDL oxidation. The U937 cells them-
selves were another possible source of transition
metal ions. When Dacron graft material, LDL, and
cells were incubated with three metal chelators
(EDTA, deferoxamine, and bathocuproinedisulfonic
acid), each inhibited Dacron-activated U937 cell
oxidation of LDL. These data suggest that iron and
copper are required for oxidation of the LDL, but
the source of these transition metal ions is not cer-
tain. Inhibition by the specific inhibitors, however,
does indicate the types of transition metal ions
required for Dacron-activated U937 cell oxidation
of LDL. Inhibition by deferoxamine suggests that
the iron is in the Fe3+ form. Superoxide production
by activated cells may reduce Fe3+ to Fe2+, which
accounts for the ability of EDTA to inhibit Dacron-
activated U937 cell LDL oxidation. Finally, inhibi-
tion by bathocuproinedisulfonic acid indicates the
involvement of Cu1+ in LDL oxidation induced by
Dacron-activated U937 cells.
Dacron and zymosan induce similar bursts of
superoxide production by U937 cells. Other investiga-
tors have shown that phagocytosis and the release of
reactive oxygen species are intimately linked.39
Monocytes phagocytose zymosan, but Dacron graft
segments are too large to be successfully phagocy-
tosed. Because particulate matter associated with graft
material may be phagocytosed by macrophages and
has been shown to contribute to cellular activation,44
the Dacron graft material used in our studies was sub-
jected to multiple washes with ethanol and water to
remove loose material. Control studies showed no dif-
ference in the ability of washed or unwashed Dacron
to stimulate U937 cells (data not shown), making it
unlikely that phagocytosis of particulate matter associ-
ated with the graft material activated the monocytic
cells. Previous reports have documented a “frustrated
phagocytosis” in which monocytes and macrophages
contact material that is too large for phagocytosis, yet
multiple membrane changes consistent with activation
are initiated.45 Dacron graft material may cause such a
“frustrated phagocytosis,” which induces cellular acti-
vation. Once activation is initiated, a respiratory burst
occurs with concomitant production of reactive oxy-
gen species, including superoxide, leading to LDL 
oxidation.
Extrapolation of in vitro findings to in vivo con-
ditions is difficult at best. We have shown that
Dacron graft material can activate normal human
peripheral blood monocytes, in addition to those of
a monocytic cell line, to oxidize LDL. Although the
time course for LDL oxidation by human monocytes
was slightly delayed compared with U937 cells, this
suggests that graft-activated monocytic cell oxidation
of LDL is possible in vivo. In fact, we have recently
shown that lipid oxidation products are present in
both Dacron and ePTFE grafts that were explanted
from dogs and rabbits.17 Although this may appear
to be at odds with our in vitro work that showed that
Dacron graft material more effectively activates
monocytic cells to oxidize LDL than does ePTFE,
the in vitro studies were only 24 hours in duration.
The response to graft implantation in vivo is a chron-
ic reaction. The processes that occur in Dacron and
ePTFE grafts in vivo, especially with respect to lipid
oxidation, remain speculative at this time.
In the clinical setting, we postulate that graft
implantation initiates a sequence of events leading to
LDL oxidation. Monocytes and macrophages are
recruited to the site of graft implantation, becoming
activated as part of a generalized foreign body
response to the graft, which causes the release of reac-
tive oxygen species. Concomitant with these events,
lipoprotein deposition occurs, especially at the graft
anastomoses.5,7 We postulate that these lipoproteins
are oxidized by the activated macrophages and that
these oxidized lipoproteins (and their component
lipids) inhibit EC ingrowth and stimulate SMC pro-
liferation. These dysfunctional cellular responses may
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contribute to the development of anastomotic intimal
hyperplasia and subsequent graft failure.
If oxidized lipids contribute to the development
of intimal hyperplasia, as we propose, therapies
directed at lipids may be effective in limiting hyper-
plastic lesions. Lipid-lowering regimens may limit
the amount of lipids available for oxidation and thus
slow the development of intimal hyperplasia.
Antioxidant therapy may also inhibit the formation
of lipid oxidation products, similarly decreasing the
development of anastomotic intimal hyperplasia.
We thank Meadox Medicals, Inc, for providing the
Dacron graft material and Alice Ruffo, in the laboratory of
Debra Graham, MD, for technical assistance in human
peripheral blood monocyte studies.
REFERENCES
1. Jordan GL, De Bakey ME, Halpert B. Lipid changes by
chronic hypercholesterolemia in nylon and orlon replacement
of canine thoracic aorta. Proc Soc Exp Biol Med 1958;
99:484-7.
2. Walton KW, Slaney G, Ashton F. Atherosclerosis in vascular
grafts for peripheral vascular disease. Part 2. Synthetic arteri-
al prostheses. Atherosclerosis 1986;61:155-67.
3. Chignier E, Guidollet J, Lhopital C, Louisot P, Eloy R. Lipid
accumulation in prosthetic vascular grafts: experimental
study. Am J Pathol 1990;137:531-40.
4. Wagner E, Guidoin R, Marois M, et al. Histopathologic find-
ings in synthetic and biologic explanted grafts used in periph-
eral arterial reconstruction. ASAIO 1994;40:M279-83.
5. Baumann DS, Doblas M, Daugherty A, Sicard G, Schonfeld
G. The role of cholesterol accumulation in prosthetic vascu-
lar graft anastomotic intimal hyperplasia. J Vasc Surg 1994;
19:435-45.
6. De Bakey ME, Jordan GL, Beall AC, O’Neal RM, Abbott JP,
Halpert B. Basic biologic reactions to vascular grafts and
prostheses. Surg Clin North Am 1965;45:477-97.
7. Miller A, Schoen FJ, Lees AM, Fallon JT, Strauss HW, Lees
RS. Low density lipoprotein accumulation by PTFE grafts in
the rabbit aorta: autoradiographic-morphologic correlations.
ASAIO Trans 1987;33:489-93.
8. Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, et al. Gene
expression in macrophage-rich human atherosclerotic lesions.
15-lipoxygenase and acetyl low density lipoprotein receptor
messenger RNA colocalize with oxidation specific lipid-pro-
tein adducts. J Clin Invest 1991;87:1146-52.
9. Salmon S, Maziere C, Theron L, et al. Immunological detec-
tion of low-density lipoproteins modified by malondialde-
hyde in vitro or in vivo. Biochim Biophys Acta 1987;
920:215-20.
10. Quinn MT, Parthasarathy S, Fong LG, Steinberg D.
Oxidatively modified low density lipoproteins: a potential
role in recruitment and retention of monocyte/macrophages
during atherogenesis. Proc Natl Acad Sci U S A 1987;
84:2995-8.
11. Henriksen T, Mahoney EM, Steinberg D. Enhanced
macrophage degradation of biologically modified low densi-
ty lipoprotein. Arteriosclerosis 1983;3:149-59.
12. Murugesan G, Chisolm GM, Fox PL. Oxidized low density
lipoprotein inhibits the migration of aortic endothelial cells in
vitro. J Cell Biol 1993;120:1011-9.
13. Chatterjee S. Role of oxidized human plasma low density
lipoproteins in atherosclerosis: effects on smooth muscle cell
proliferation. Mol Cell Biochem 1992;111:143-7.
14. Lafont AM, Chai Y-C, Cornhill JF, Whitlow PL, Howe PH,
Chisolm GM. Effect of alpha-tocopherol on restenosis after
angioplasty in a model of experimental atherosclerosis. J Clin
Invest 1995;95:1018-25.
15. Chen Y, Morimoto S, Kitano S, et al. Lysophosphatidylcholine
causes Ca2+ influx, enhanced DNA synthesis and cytotoxicity
in cultured vascular smooth muscle cells. Atherosclerosis
1995;112:69-76.
16. Jimi S, Saku K, Uesugi N, Sakata N, Takebayashi S. Oxidized
low density lipoprotein stimulates collagen production in cul-
tured arterial smooth muscle cells. Atherosclerosis 1995;
116:15-26.
17. van Aalst JA, Fox PL, Graham LM. Lipid oxidation products
in implanted vascular grafts. Surg Forum 1998;49:324-6.
18. Piotrowski JJ, Hunter GC, Eskelson CD, et al. Lipid peroxi-
dation: a possible factor in late graft failure of coronary artery
bypass grafts. J Vasc Surg 1991;13:652-7.
19. Steinbrecher UP. Role of superoxide in endothelial-cell mod-
ification of low-density lipoproteins. Biochim Biophys Acta
1988;959:20-30.
20. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sul-
fur-containing amino acids in superoxide production and
modification of low density lipoprotein by arterial smooth
muscle cells. J Biol Chem 1987;262:10098-103.
21. Ferns GA, Lamb DJ, Taylor A. The possible role of copper
ions in atherogenesis: the Blue Janus. Atherosclerosis 1997;
133:139-52.
22. Corti MC, Gaziano M, Hennekens CH. Iron status and risk
of cardiovascular disease. Ann Epidemiol 1997;7:62-8.
23. McNally AK, Chisolm GM, Morel DW, Cathcart MK.
Activated human monocytes oxidize low-density lipoprotein
by a lipoxygenase-dependent pathway. J Immunol 1990;
145:254-9.
24. Cathcart MK, McNally AK, Morel DW, Chisolm GM.
Superoxide anion participation in human monocyte-mediat-
ed oxidation of low-density lipoprotein and conversion of
low-density lipoprotein to a cytotoxin. J Immunol 1989;142:
1963-9.
25. Cathcart MK, Chisolm GM, McNally AK, Morel DW.
Oxidative modification of low density lipoprotein (LDL) by
activated human monocytes and the cell lines U937 and
HL60. In Vitro Cell Dev Biol 1988;24:1001-8.
26. Xing X, Baffic J, Sparrow CP. LDL oxidation by activated
monocytes: characterization of the oxidized LDL and
requirement for transition metal ions. J Lipid Res 1998;39:
2201-8.
27. Hanson SR, Reidy MA, Hattori A, Harker LA. Pharm-
acologic modification of acute vascular graft thrombosis.
Scanning Electron Microsc 1982;2:773-9.
28. Bonfield TL, Colton E, Marchant RE, Anderson JM. Cytokine
and growth factor production by monocytes/macrophages on
protein preadsorbed polymers. J Biomed Mater Res 1992;
26:837-50.
29. Cardona MA, Simmons RL, Kaplan SS. TNF and IL-1 gen-
eration by human monocytes in response to biomaterials. J
Biomed Mater Res 1992;26:851-9.
30. Hessler JR, Morel DW, Lewis LJ, Chisolm GM. Lipoprotein
oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis
1983;3:215-22.
JOURNAL OF VASCULAR SURGERY
Volume 31, Number 1, Part 1 van Aalst et al 179
31. Miltenyi S, Muller W, Weichel W, Radbruch A. High gradi-
ent magnetic cell separation with MACS. Cytometry
1990;11:231-8.
32. Schuh J, Fairclough GF, Haschemeyer RH. Oxygen-mediat-
ed heterogeneity of apo-low-density lipoprotein. Proc Natl
Acad Sci U S A 1978;75:3173-7.
33. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous
monitoring of in vitro oxidation of human low density
lipoprotein. Free Radic Res Commun 1989;6:67-75.
34. El-Saadani M, Esterbauer H, El-Sayed M, Goher M, Nassar
AY, Jurgens G. A spectrophotometric assay for lipid perox-
ides in serum lipoproteins using a commercially available
reagent. J Lipid Res 1989;30:627-30.
35. McCord JM, Fridovich I. Superoxide dismutase: an enzymic
function for erythrocuprein (hemocuprein). J Biol Chem
1969;244:6049-55.
36. Heinecke JW, Baker L, Rosen H, Chait A. Superoxide-medi-
ated modification of low density lipoprotein by arterial
smooth muscle cells. J Clin Invest 1986;77:757-61.
37. Jessup W, Simpson JA, Dean RT. Does superoxide radical
have a role in macrophage-mediated oxidative modification
of LDL? Atherosclerosis 1993;99:107-20.
38. Salo DC, Pacifici RE, Lin SW, Giulivi C, Davies KJA.
Superoxide dismutase undergoes proteolysis and fragmenta-
tion following oxidative modification and inactivation. J Biol
Chem 1990;265:11919-27.
39. Bellavite P. The superoxide-forming enzymatic system of
phagocytes. Free Radic Biol Med 1988;4:225-61.
40. Goetz MB, Proctor RA. Effect of chelating agents and super-
oxide on human neutrophil NAD(P)H oxidation. Anal
Biochem 1984;37:230-5.
41. Morel F, Doussiere J, Vignais PV. The superoxide-generating
oxidase of phagocytic cells: physiological, molecular and
pathological aspects. Eur J Biochem 1991;201:523-46.
42. Hiramatsu K, Rosen H, Heinecke JW, Wolfbauer G, Chait A.
Superoxide initiates oxidation of low density lipoprotein by
human monocytes. Arteriosclerosis 1987;7:55-60.
43. Wardman P, Candeias LP. Fenton chemistry: an introduction.
Radiat Res 1996;145:523-31.
44. Greisler HP, Dennis JW, Endean ED, Ellinger J, Friesel R,
Burgess W. Macrophage/biomaterial interactions: the stimu-
lation of endothelialization. J Vasc Surg 1989;9:588-93.
45. Bainton DF, Takemura R, Stenberg PE, Werb Z. Rapid frag-
mentation and reorganization of Golgi membranes during
frustrated phagocytosis of immobile immune complexes by
macrophages. Am J Pathol 1989;134:15-26.
Submitted Jun 11, 1998; accepted Jun 30, 1999.
JOURNAL OF VASCULAR SURGERY
180 van Aalst et al January 2000
